Didanosine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Didanosine}} | {{Didanosine}} | ||
| Line 8: | Line 7: | ||
The following adverse reactions are discussed in greater detail in other sections<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = }}</ref>: | The following adverse reactions are discussed in greater detail in other sections<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = }}</ref>: | ||
* | * [[Pancreatitis]] | ||
* | * [[Lactic acidosis]]/severe [[hepatomegaly]] with [[steatosis]] | ||
* | * Hepatic toxicity | ||
* | * Non-cirrhotic [[portal hypertension]] | ||
* | * [[Peripheral neuropathy]] | ||
* | * Retinal changes and [[optic neuritis]] | ||
==References== | ==References== | ||
Revision as of 05:52, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections[1]:
- Lactic acidosis/severe hepatomegaly with steatosis
- Hepatic toxicity
- Non-cirrhotic portal hypertension
- Retinal changes and optic neuritis
References
Adapted from the FDA Package Insert.